Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trisenox in recurrent or metastatic endometrial adenocarcinoma
NCT01184053Phase 2
Key facts
- Status
- Terminated
- Start
- Mar 2010
- Primary completion
- Mar 2012
- Countries
- 1
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Drugs
- arsenic trioxide
- Conditions
- endometrial adenocarcinoma
01
Overview
Phase 2, open-label trial of arsenic trioxide in endometrial adenocarcinoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 28 days. Started Mar 2010; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Beyond the preview
Go deeper on NCT01184053.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01184053.